ClinicalTrials.gg
CompletedNCT03950739BREEZEUpdated Nov 1, 2024Results posted

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

A Phase 1 interventional study of Treprostinil Inhalation Powder in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by United Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
13th of 44
51 · median 32
Started
2019
with 4 others
Phase 1
9 of 44
none open now
Registered
37th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 13th largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 1, and was the 37th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.

Read the detailed description

United Therapeutics Corporation (UTC) developed a combination drug-device product comprised of a dry powder formulation of Treprostinil Inhalation Powder (TreT) and a small, portable, dry powder inhaler. In this Phase 1b safety and tolerability study, patients with PAH on a stable dose of Tyvaso (6 to 12 breaths 4 times daily [QID]) were evaluated after switching to a corresponding dose of TreT. Patients underwent PK assessments, safety assessments, a 6-Minute Walk Test (6MWT), and questionnaires for satisfaction/preference for inhaled devices and patient-reported PAH symptoms and impact. Following 3 weeks of treatment with TreT, patients were offered the opportunity to participate in the Optional Extension Phase until the drug/device became commercially available.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • prostacyclin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject voluntarily gave to participate in the study.
  2. Subject was aged 18 years or older at the time of signing informed consent.
  3. Women of were those who had experienced menarche and who had not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or were not (defined as amenorrhea for at least 12 consecutive months). WOCBP must have been nonpregnant (as confirmed by a urine pregnancy test at Screening prior to initiating study medication), nonlactating, and did 1 of the following:

    1. Abstained from intercourse (when it was in line with their preferred and usual lifestyle), or
    2. Used 2 medically acceptable, highly effective forms of for the duration of study, and at least 30 days after discontinuing TreT. Medically acceptable, highly effective forms of contraception included approved hormonal contraceptives (oral, injectable, and implantable), intrauterine devices or systems, and barrier methods (such as a condom or diaphragm) when used with a spermicide.
  4. Males with a partner of childbearing potential must have used a condom for the duration of treatment and for at least 48 hours after discontinuing TreT.
  5. Subject was diagnosed with PAH as defined by the following World Health Organization (WHO) Group 1 categories:

    1. Idiopathic/familial
    2. Associated with unrepaired or repaired congenital systemic-to-pulmonary shunts (repaired ≥5 years prior to Screening)
    3. Associated with collagen vascular disease
    4. Associated with
    5. Associated with appetite suppressant/other drug or toxin use
  6. Subject must have started Tyvaso ≥3 months prior to the Baseline Visit and was currently on a stable regimen (no change in dose within 30 days of Baseline Visit) of Tyvaso (6 to 12 breaths QID).
  7. Baseline 6MWD ≥150 m.
  8. If the subject was currently receiving other approved background therapy (eg, endothelin receptor antagonist or phosphodiesterase type 5 inhibitor or both), the subject must have been on a stable dose with no additions or discontinuations for a minimum of 30 days prior to Screening.
  9. The subject had evidence of (FEV1) ≥60% and FEV1/forced vital capacity ratio ≥60% during the 6 months prior to enrollment.
  10. In the opinion of the Investigator, the subject was able to communicate effectively with study personnel, and was considered reliable, willing, and likely to be cooperative with protocol requirements, including all study visits.

Exclusion criteria

Exclusion Criteria:

  1. Subject was pregnant or lactating.
  2. Subject was diagnosed with pulmonary hypertension for reasons other than WHO Group 1 as outlined in Inclusion Criterion 5 (including but not limited to portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease, hemolytic anemia, sarcoidosis).
  3. Subject had a history of uncontrolled sleep apnea, parenchymal lung disease, or hemodynamically significant left-sided heart disease (including but not limited to aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, or coronary artery disease).
  4. Subject was currently taking any other prostacyclin analogue or agonist, including but not limited to selexipag, epoprostenol, iloprost, or beraprost; except for acute vasoreactivity testing.
  5. Subject experienced an acute exacerbation of disease or hospitalization for any reason within 30 days of the Screening Visit or between Screening and Baseline.
  6. Subject was WHO Functional Class IV at Screening.
  7. Subject had used any drug/device or participated in any other investigational study with therapeutic intent within 30 days prior to the Screening Visit.
  8. Subject had a history of anaphylaxis, a documented reaction, or a idiosyncratic reaction to treprostinil or in the investigational product.
  9. Subject had conditions that, in the opinion of the Investigator, would make the subject ineligible.
  10. Subject was not able to perform inhalation maneuvers that met inspiratory training criteria.
  11. Subject had a musculoskeletal disorder (eg, arthritis affecting the lower limbs, recent hip or knee joint replacement) or any disease that would likely be the primary limit to ambulation, or was connected to a machine that was not portable enough to allow for a 6MWT.
  12. Subject had a new type of chronic therapy (including but not limited to oxygen, a different class of vasodilator, diuretic, and digoxin) for pulmonary hypertension added within 30 days of the Screening Phase.
  13. Initiation of pulmonary rehabilitation within 12 weeks prior to the Baseline Visit.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Tyvaso to TreT

    Each subject received a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.

    Drug: Treprostinil Inhalation Powder

Interventions

  • Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)

    Also known as: TreT

06

What researchers measure

Primary outcomes

  1. Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 3

    6MWD was evaluated at study entry and after 3 weeks of treatment with TreT.

    Time frame: From Baseline to 3 weeks of treatment with TreT

  2. Subject Satisfaction With and Preference for Inhaled Treprostinil Devices

    Subject satisfaction with and preference for the inhaled treprostinil device was evaluated with the Preference Questionnaire for Inhaled Treprostinil Devices (PQ-ITD). The PQ-ITD is a questionnaire given to evaluate subject satisfaction with and preference for inhaled treprostinil devices. The questionnaire provides 12 different statements around inhaled device satisfaction and allows for 5 response options: strongly disagree, disagree, neutral, agree, and strongly agree.

    Time frame: After 3 weeks of treatment with TreT (after switching from the Tyvaso Inhalation System)

  3. Change in Patient-reported PAH Symptoms and Impact From Baseline to Week 3

    Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.

    Time frame: From Baseline to 3 weeks of treatment with TreT

  4. Change in Patient-reported PAH Symptoms and Impact From Baseline to Week 11 (for Subjects Participating in the OEP)

    Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.

    Time frame: From Baseline to 11 weeks of treatment with TreT

07

Results

Posted Nov 1, 2024

Participant flow

Treatment Phase
Participant flow — Treatment Phase
MilestoneTyvaso to TreT
Started51
Completed49
Not completed2
Withdrew: Adverse event2
Optional Extension Phase
Participant flow — Optional Extension Phase
MilestoneTyvaso to TreT
Started49
Completed31
Not completed18
Withdrew: Death1
Withdrew: Progressive disease5
Withdrew: Adverse event7
Withdrew: Lost to follow-up2
Withdrew: Site closure2
Withdrew: Pregnancy1

Outcome measures

PrimaryChange in 6-Minute Walk Distance (6MWD) From Baseline to Week 3

6MWD was evaluated at study entry and after 3 weeks of treatment with TreT.

Time frame:
From Baseline to 3 weeks of treatment with TreT
Reported as:
Mean · meters
Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 3
metersTyvaso to TreT
Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 311.5 ± 32.9
PrimarySubject Satisfaction With and Preference for Inhaled Treprostinil Devices

Subject satisfaction with and preference for the inhaled treprostinil device was evaluated with the Preference Questionnaire for Inhaled Treprostinil Devices (PQ-ITD). The PQ-ITD is a questionnaire given to evaluate subject satisfaction with and preference for inhaled treprostinil devices. The questionnaire provides 12 different statements around inhaled device satisfaction and allows for 5 response options: strongly disagree, disagree, neutral, agree, and strongly agree.

Time frame:
After 3 weeks of treatment with TreT (after switching from the Tyvaso Inhalation System)
Reported as:
Count of participants · Participants
Subject Satisfaction With and Preference for Inhaled Treprostinil Devices
ParticipantsTyvaso to TreT
Strongly Disagree0
Disagree0
Neutral1
Agree5
Strongly Agree40
PrimaryChange in Patient-reported PAH Symptoms and Impact From Baseline to Week 3

Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.

Time frame:
From Baseline to 3 weeks of treatment with TreT
Reported as:
Mean · score on a scale
Change in Patient-reported PAH Symptoms and Impact From Baseline to Week 3
score on a scaleTyvaso to TreT
Cardiopulmonary Symptoms Domain Score-0.05 ± 0.27
Cardiovascular Symptoms Domain Score-0.06 ± 0.33
Physical Impacts Domain Score-0.14 ± 0.46
Cognitive/Emotional Impacts Domain Score-0.17 ± 0.40
PrimaryChange in Patient-reported PAH Symptoms and Impact From Baseline to Week 11 (for Subjects Participating in the OEP)

Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.

Time frame:
From Baseline to 11 weeks of treatment with TreT
Reported as:
Mean · score on a scale
Change in Patient-reported PAH Symptoms and Impact From Baseline to Week 11 (for Subjects Participating in the OEP)
score on a scaleTyvaso to TreT
Cardiopulmonary Symptoms Domain Score-0.04 ± 0.36
Cardiovascular Symptoms Domain Score-0.05 ± 0.40
Physical Impacts Domain Score-0.20 ± 0.59
Cognitive/Emotional Impacts Domain Score-0.13 ± 0.51

Adverse events

Collected over All AEs were documented from the time of informed consent until the time screen failure was documented, until the subject either discontinued from the study, or the End of Study (EOS)/Early Termination (ET) assessments were completed, up to 201.1 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tyvaso to TreT 32 mcg (Treatment Phase)0/2 (0%)0/2 (0%)0/2 (0%)
Tyvaso to TreT 48 mcg (Treatment Phase)0/27 (0%)1/27 (3.7%)17/27 (63%)
Tyvaso to TreT 64 mcg (Treatment Phase)0/22 (0%)1/22 (4.5%)14/22 (63.6%)
Tyvaso to TreT 32 mcg (Optional Extension Phase)0/2 (0%)1/2 (50%)2/2 (100%)
Tyvaso to TreT 48 mcg (Optional Extension Phase)0/26 (0%)12/26 (46.2%)25/26 (96.2%)
Tyvaso to TreT 64 mcg (Optional Extension Phase)1/21 (4.8%)12/21 (57.1%)20/21 (95.2%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventTyvaso to TreT 32 mcg (Treatment Phase)Tyvaso to TreT 48 mcg (Treatment Phase)Tyvaso to TreT 64 mcg (Treatment Phase)Tyvaso to TreT 32 mcg (Optional Extension Phase)Tyvaso to TreT 48 mcg (Optional Extension Phase)Tyvaso to TreT 64 mcg (Optional Extension Phase)
Post procedural haemorrhageInjury, poisoning and procedural complications0/20/270/221/20/260/21
Procedural painInjury, poisoning and procedural complications0/20/270/221/20/260/21
HypotensionVascular disorders0/20/270/221/20/260/21
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders0/20/270/220/23/260/21
CellulitisInfections and infestations0/20/270/220/20/262/21
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/20/270/220/20/262/21
PneumoniaInfections and infestations0/20/270/220/22/260/21
SyncopeNervous system disorders0/20/270/220/22/260/21
Right ventricular failureCardiac disorders0/20/270/220/21/261/21
Atrioventricular blockCardiac disorders0/20/270/220/20/261/21
Most frequent other events
Showing 10 of 53
Most frequent other events
EventTyvaso to TreT 32 mcg (Treatment Phase)Tyvaso to TreT 48 mcg (Treatment Phase)Tyvaso to TreT 64 mcg (Treatment Phase)Tyvaso to TreT 32 mcg (Optional Extension Phase)Tyvaso to TreT 48 mcg (Optional Extension Phase)Tyvaso to TreT 64 mcg (Optional Extension Phase)
HeadacheNervous system disorders0/24/274/222/26/264/21
DyspnoeaRespiratory, thoracic and mediastinal disorders0/22/272/222/210/264/21
NauseaGastrointestinal disorders0/22/271/222/22/264/21
CoughRespiratory, thoracic and mediastinal disorders0/211/277/221/24/264/21
DiarrhoeaGastrointestinal disorders0/20/272/221/24/264/21
AnaemiaBlood and lymphatic system disorders0/20/270/221/21/262/21
VomitingGastrointestinal disorders0/20/271/221/24/261/21
Oesophageal painGastrointestinal disorders0/20/270/221/20/260/21
Chest painGeneral disorders0/21/270/221/22/260/21
AstheniaGeneral disorders0/20/270/221/20/260/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tyvaso to TreT
Median57.0 (23 to 82)
Age, Customized
Age, Customized(Participants)Tyvaso to TreT
<65 years38
≥65 years13
Sex: Female, Male
Sex: Female, Male(Participants)Tyvaso to TreT
Female43
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tyvaso to TreT
Hispanic or Latino4
Not Hispanic or Latino47
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tyvaso to TreT
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American9
White40
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Tyvaso to TreT
United States51
Time Since PAH Diagnosis
Time Since PAH Diagnosis(years)Tyvaso to TreT
Median7.820 (0.49 to 30.88)
Current PAH Diagnosis
Current PAH Diagnosis(Participants)Tyvaso to TreT
Idiopathic/Familial29
Associated with Unrepaired or Repaired Congenital Systemic-to-Pulmonary Shunts4
Associated with Collagen Vascular Disease14
Associated with HIV1
Associated with Appetite Suppressant/Other Drug or Toxin Use3

2 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Department of Veterans Affairs Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Ascension / St. Vincent's Lung Institute
    Jacksonville, Florida 32204, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • University of South Florida Center for Advanced Lung Disease
    Tampa, Florida 33606, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Louisville Clinical Trials Unit
    Louisville, Kentucky 40202, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • University of Maryland Medical Center Division of Cardiology
    Baltimore, Maryland 21201, United States
  • Penn Medicine University City
    Philadelphia, Pennsylvania 19104, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23230, United States
09

References and documents

Publications

  • Spikes LA, Bajwa AA, Burger CD, Desai SV, Eggert MS, El-Kersh KA, Fisher MR, Johri S, Joly JM, Mehta J, Palevsky HI, Ramani GV, Restrepo-Jaramillo R, Sahay S, Shah TG, Deng C, Miceli M, Smith P, Shapiro SM. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI in patients with pulmonary arterial hypertension. Pulm Circ. 2022 Apr 7;12(2):e12063. doi: 10.1002/pul2.12063. eCollection 2022 Apr. PubMed 35514770 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Aug 2023, 47 months.

Results were first posted in Nov 2024, 1 year 2 months after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 47 months is above that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 15, 2019
StartActual
Sep 17, 2019
Primary completionActual
Aug 22, 2023
CompletionActual
Aug 22, 2023
Results first posted
Nov 1, 2024
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03950739
Responsible party
Sponsor
First posted
May 15, 2019
Start date
Sep 17, 2019
Primary completion
Aug 22, 2023
Completion
Aug 22, 2023
Results posted
Nov 1, 2024
Last update
Nov 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion